The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Remsima

120 milligram(s)/millilitre Solution for injection in pre-filled syringe

Celltrion Healthcare Hungary Kft.EU/1/13/853/006-011

Main Information

Trade NameRemsima
Active SubstancesInfliximab
Strength120 milligram(s)/millilitre
Dosage FormSolution for injection in pre-filled syringe
Licence HolderCelltrion Healthcare Hungary Kft.
Licence NumberEU/1/13/853/006-011

Group Information

ATC CodeL04AB02 infliximab

Status

Authorised/WithdrawnAuthorised
Licence Issued22/11/2019
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website

Educational Materials - Patient

« Back